On May 28, 2026 Sapu Nano and Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") reported that Vuong Trieu, Chief Executive Officer, reported it will present the Company’s Deciparticle nanomedicine platform at the BIO International Convention 2026 in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will focus on Oncotelic’s development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics that are otherwise difficult or impossible to formulate using conventional technologies.

The Deciparticle platform is based on proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. The Company believes the platform may enable improved aqueous compatibility, reduced reliance on toxic excipients, enhanced manufacturability, and broader development flexibility for challenging compounds.

At BIO 2026, the Company plans to highlight development progress across multiple Deciparticle programs, including:

Sapu006, a polysorbate-free intravenous docetaxel formulation currently moving into Phase 1b clinical evaluation;
Sapu003, an intravenous everolimus nanomedicine program designed to potentially reduce gastrointestinal exposure associated with oral administration currently in a global Phase 1b clinical trial; and
Broader applications of the Deciparticle platform for difficult-to-formulate small molecules and macrolide therapeutics.
The Company will also discuss how artificial intelligence and knowledge-organization technologies are being integrated into formulation development, manufacturing intelligence, and translational oncology workflows through its PDAOAI platform.

"Many important therapeutics remain limited by formulation complexity, poor aqueous solubility, excipient-related toxicity, or manufacturing challenges," said Vuong Trieu, Chief Executive Officer. "Our objective with Deciparticle is to create a scalable nanomedicine platform capable of enabling intravenous delivery of highly insoluble molecules while simplifying formulation architecture and supporting clinical translation."

According to the Company, Deciparticle formulations are designed to address key limitations associated with conventional solubilizing systems, including hypersensitivity reactions, surfactant burden, formulation instability, and manufacturing complexity.

Oncotelic believes the combination of nanomedicine engineering, translational oncology, manufacturing expertise, and AI-driven scientific cognition may provide a differentiated platform for future drug development.

BIO International Convention is one of the biotechnology industry’s largest partnering and innovation events, bringing together biotechnology companies, pharmaceutical companies, investors, and scientific leaders from around the world.

About Deciparticle

Deciparticle is Oncotelic’s proprietary nanomedicine platform designed to formulate highly water-insoluble therapeutics into ultra-small nanoparticles for intravenous administration. The platform utilizes amphiphilic polymer architectures intended to improve aqueous compatibility, stability, manufacturability, and translational flexibility across multiple therapeutic classes.

(Press release, Oncotelic, MAY 28, 2026, View Source [SID1234666157])

On May 28, 2026 Daiichi Sankyo (TSE: 4568) reported it will present new clinical research across its oncology portfolio with more than 25 abstracts in multiple cancers at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (#ASCO26).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data at ASCO (Free ASCO Whitepaper) will highlight the company’s progress toward advancing new standards of care for patients with cancer, including new analyses from five landmark trials in breast and gastric cancer, including the DESTINY-Breast05 (#516), DESTINY-Breast06 (#1063), DESTINY-Breast09 (#1021) and DESTINY-Gastric04 (#4111) phase 3 trials of Enhertu (trastuzumab deruxtecan), and the TROPION-Breast02 (#1002) phase 3 trial of Datroway (datopotamab deruxtecan). Additional results from earlier phase trials as well as trials-in-progress across new medicines being developed through the company’s breakthrough generating technology (BGT), a platform-based drug discovery model designed to deliver innovative medicines to patients faster, will be highlighted.

Data from DESTINY-Breast05 formed the basis of one of two new Enhertu indications recently approved in the U.S. for certain patients with early-stage HER2 positive breast cancer and data from DESTINY-Gastric04 was included as part of a label update to expand the use of Enhertu in Japan and China to include the second-line treatment of patients with HER2 positive metastatic gastric cancer. Additionally, results from TROPION-Breast02 formed the basis of the recent U.S. approval of Datroway in patients with metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy, the first antibody drug conjugate (ADC) to be approved in this setting of TNBC.

"The approvals received just prior to ASCO (Free ASCO Whitepaper) for Enhertu and Datroway, two of our leading DXd antibody drug conjugates, together with the strong science being showcased across our pipeline, highlight the momentum of our oncology portfolio," said John Tsai, MD, Global Head, R&D, Daiichi Sankyo. "Daiichi Sankyo is committed to creating new standards of care for patients with cancer and continues to leverage its scientific and technological expertise to advance innovation."

Additional Enhertu Data Spans Broad Range of HER2 Expressing Cancers
Additional research updates across several additional HER2 expressing cancers include oral and poster sessions highlighting the preliminary safety run-in results from the DESTINY-Ovarian01 (#5554) phase 3 trial evaluating Enhertu in combination with bevacizumab compared to bevacizumab monotherapy as a first-line maintenance therapy in patients with HER2 expressing ovarian cancer; the primary analysis from part 1 of the DESTINY-PanTumor03 (#3026) phase 2 trial evaluating Enhertu in pretreated patients in China with HER2 positive (IHC 3+) solid tumors (excluding breast and gastric cancer); and, findings from the MYTHOS (#6011) phase 2 trial evaluating Enhertu in patients with HER2-low recurrent or metastatic salivary gland cancer.

Additional breast and gastric cancer data for Enhertu include an oral presentation from one arm of the DESTINY-Breast07 (#1012) phase 1b/2 trial evaluating Enhertu in combination with durvalumab as a first-line treatment in patients with HER2 positive metastatic breast cancer and a poster presentation highlighting a safety analysis from the DESTINY-Gastric03 (#4022) phase 1b/2 trial evaluating Enhertu in combination with chemotherapy and immunotherapy as a first-line treatment in patients with HER2 expressing metastatic gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma or esophageal adenocarcinoma.

Results from cohort two of the EPOC2203 (#4024) phase 1b/2 trial evaluating Enhertu in combination with nivolumab and capecitabine and oxaliplatin in patients with HER2 low gastroesophageal adenocarcinoma and an exploratory analysis of translational data from the EPOC2003 (#3129) phase 2 trial evaluating neoadjuvant chemotherapy in combination with Enhertu in patients with HER2 positive gastric cancer will be highlighted as poster presentations.

New Data and Trials-in-Progress Presentations Across Oncology Portfolio
Poster presentations will include a trial-in-progress update of REJOICE-Ovarian01 (TPS5637) for the phase 3 part of a phase 2/3 trial evaluating raludotatug deruxtecan (R-DXd) compared to treatment of physician’s choice in patients with platinum-resistant ovarian cancer. Two additional poster presentations will highlight an exposure-response analysis (#5570) and a population pharmacokinetic analysis (#5571) of data from both the REJOICE-Ovarian01 phase 2/3 trial and the phase 1 trial evaluating raludotatug deruxtecan in patients with advanced ovarian cancer or renal cell carcinoma.

An oral presentation will highlight results from a phase 1/2 trial (#6504) of Vanflyta (quizartinib) plus decitabine and venetoclax in patients with newly diagnosed or relapsed/refractory FLT3-ITD acute myeloid leukemia.

Trials-in-progress poster presentations across the DXd ADC portfolio include the TROPION-Urothelial03 (TPS4642) phase 2/3 trial evaluating Datroway and platinum chemotherapy compared to gemcitabine plus platinum chemotherapy in patients with locally advanced or metastatic urothelial carcinoma; the HERTHENA-Breast04 (TPS1149) phase 3 trial evaluating patritumab deruxtecan (HER3-DXd) compared to treatment of physician’s choice in patients with HR positive, HER2 negative unresectable locally advanced or metastatic breast cancer; and the DESTINY-PanTumor04 (TPS11202) hybrid observational trial evaluating Enhertu in patients with HER2 positive (IHC 3+) solid tumors.

Trials-in-Progress Presentations Highlight Breakthrough Generating Technology Focus
Daiichi Sankyo is leveraging its strength in science and technology to create new medicines for patients with cancer through its BGT approach which is designed to deliver innovative medicines to patients faster and with a higher probability of success. Trials-in-progress poster presentations featuring three potential new medicines include DS3610 (TPS3159), a STING (stimulator of interferon genes) ADC, in patients with advanced or metastatic solid tumors; DS5361 (TPS2680), a small-molecule, nonsense-mediated mRNA decay inhibitor, in patients with advanced or metastatic solid tumors; and, DS9051 (TPS3179), a novel targeted protein degradation molecule, in patients with advanced or metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer.

Overview of clinical data and trials-in-progress from oncology pipeline of Daiichi Sankyo include:

Presentation Title

Author

Abstract

Presentation (CDT)

Breast

A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab

Y. Park

1021

Rapid Oral Presentation
Sunday, May 31
11:30 am – 1:00 pm

Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: clinical and demographic risk factors of interstitial lung disease and radiation pneumonitis

M. Untch

516

Rapid Oral Presentation
Monday, June 1
9:45 – 11:15 am

Neoadjuvant rilvegostomig (R) + trastuzumab deruxtecan (T-DXd) in high-risk HER2-negative breast cancer: Results from the I-SPY 2.2 trial

C. O’Sullivan

LBA514

Rapid Oral Presentation
Monday, June 1
9:45 – 11:15 am

Trastuzumab deruxtecan (T-DXd) + durvalumab in patients with previously untreated HER2 positive unresectable/metastatic breast cancer (mBC): final analysis from DESTINY-Breast07

S. Loi

1012

Oral Presentation
Sunday, May 31
8:30 – 10:00 am

First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple negative breast cancer for whom immunotherapy was not an option: additional efficacy endpoints from the TROPION-Breast02 study

D. Cescon

1002

Oral Presentation
Tuesday, June 2
9:45 am – 12:45 pm

Impact of adherence to interstitial lung disease (ILD)/pneumonitis toxicity management guidelines on ILD/pneumonitis outcomes: a retrospective analysis of patients treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Breast06

C. Mateo

1063

Poster Session
Monday, June 1
1:30 – 4:30 pm

HERTHENA-Breast04: a phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician’s choice in hormone receptor positive (HR +)/HER2-) unresectable locally advanced or metastatic breast cancer

B. Pistilli

TPS1149

Poster Session
Monday, June 1
1:30 – 4:30 pm

Identifying patients with human epidermal growth factor receptor 2 (HER2) low and ultralow breast cancer: use of digital, artificial intelligence-based computational algorithms to assist HER2 scoring by pathologists

S. Krishnamurthy

1022

Poster Session
Monday, June 1
1:30 – 4:30 pm

Gastric

Additional health-related quality of life analysis from DESTINY-Gastric04, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs ramucirumab + paclitaxel in patients with HER2 positive unresectable/metastatic gastric cancer/gastroesophageal junction adenocarcinoma

K. Shitara

4111

Poster Session
Saturday, May 30
9:00 am – 12:00 pm

First-line trastuzumab deruxtecan (T-DXd)-based regimens in advanced HER2 expressing gastric cancer, gastroesophageal junction adenocarcinoma, or esophageal adenocarcinoma: safety results from DESTINY-Gastric03 Part 2 arms D and F, and Part 4

Y. Janjigian

4022

Poster Session
Saturday, May 30
9:00 am – 12:00 pm

An open-label phase 1b/2 study of trastuzumab deruxtecan combined with nivolumab and CAPOX in patients with HER2 low gastroesophageal adenocarcinoma (EPOC2203)

Y. Aoki

4024

Poster Session
Saturday, May 30
9:00 am – 12:00 pm

Tumor and immune microenvironment remodeling with neoadjuvant trastuzumab deruxtecan in HER2 positive gastric cancer: exploratory analyses from the phase 2 EPOC2003 study

A. Kawazoe

3129

Poster Session
Saturday, May 30
1:30 – 4:30 pm

Ovarian

Trastuzumab deruxtecan (T-DXd) + bevacizumab (BEV) as first-line (1L) maintenance therapy in patients with HER2 expressing ovarian cancer: results from the DESTINY-Ovarian01 safety run-in

A. Gonzalez Martin

5554

Poster Session
Monday, June 1
9:00 am – 12:00 pm

REJOICE-Ovarian01: phase 3 part of a phase 2/3 study evaluating raludotatug deruxtecan (R-DXd) versus treatment of physician’s choice in patients with platinum-resistant ovarian cancer

D. Richardson

TPS5637

Poster Session
Monday, June 1
9:00 am – 12:00 pm

Exposure-response analyses of efficacy and safety with raludotatug deruxtecan (R-DXd), a CDH6-directed ADC, to inform dose selection for phase 3 development in platinum-resistant ovarian cancer

F. Hurtado

5570

Poster Session
Monday, June 1
9:00 am – 12:00 pm

Population pharmacokinetic analysis of raludotatug deruxtecan (R-DXd), a CDH6-directed ADC, in patients with advanced ovarian cancer or renal cell carcinoma

F. Hurtado

5571

Poster Session
Monday, June 1
9:00 am – 12:00 pm

Urothelial

TROPION-Urothelial03: a phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy vs gemcitabine + platinum chemotherapy in participants with locally advanced or metastatic urothelial carcinoma with progression on or after enfortumab vedotin + pembrolizumab

M. Galsky

TPS4642

Poster Session
Sunday, May 31
9:00 am – 12:00 pm

Salivary

Trastuzumab deruxtecan in patients with HER2 low recurrent/metastatic salivary gland carcinoma: results from the phase 2 MYTHOS trial

I. Kinoshita

6011

Oral Presentation
Monday, June 1
8:00 – 9:30 am

AML

Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed/refractory FLT3 mutated acute myeloid leukemia

M. Yilmaz

6504

Oral Presentation
Tuesday, June 2
9:45 am – 12:45 pm

Pan Tumor

Trastuzumab deruxtecan (T-DXd) for pretreated patients in China with HER2 IHC 3+ solid tumors: DESTINY-PanTumor03 Part 1 primary analysis

Y. Zhang

3026

Poster Session
Saturday, May 30
1:30 – 4:30 pm

A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with HER2 IHC3+ solid tumors: DESTINY-PanTumor04

B. Monk

TPS11202

Poster Session
Monday, June 1
9:00 am – 12:00 pm

HER2 independent antitumor and pharmacodynamic responses to trastuzumab deruxtecan in patients with advanced solid tumors

S. Shin

3031

Poster Session
Saturday, May 30
1:30 – 4:30 pm

Topoisomerase 1 and DNA damage: pharmacodynamic responses and mechanism of trastuzumab deruxtecan in HER2-expressing advanced solid tumors

D. Wilsker

3092

Poster Session
Saturday, May 30
1:30 – 4:30 pm

BGT

A phase 1, first-in-human study of DS3610, a stimulator of interferon genes (STING) agonist ADC, in patients with advanced/metastatic solid tumors

S. Koganemaru

TPS3159

Poster Session
Saturday, May 30
1:30 – 4:30 pm

A phase 1, first-in-human study of DS5361, a small-molecule, nonsense-mediated mRNA decay inhibitor, in patients with advanced/metastatic solid tumors (Parts 1 and 2)

S. Sen

TPS2680

Poster Session
Saturday, May 30
1:30 – 4:30 pm

A phase 1, first-in-human study of DS9051, a novel targeted protein degradation molecule, in patients with advanced/metastatic adrenocortical carcinoma or metastatic castration-resistant prostate cancer

M. Patel

TPS3179

Poster Session
Saturday, May 30
1:30 – 4:30 pm

(Press release, Daiichi Sankyo, MAY 28, 2026, https://www.businesswire.com/news/home/20260528097415/en/Daiichi-Sankyo-Showcases-Progress-Across-Industry-Leading-Oncology-Portfolio-with-Latest-Research-Updates-at-ASCO [SID1234666173])

On May 27, 2026 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported its participation in the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 11:05 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 30 days.

(Press release, Cogent Biosciences, MAY 27, 2026, View Source [SID1234666094])

On May 27, 2026 AstraZeneca reported that the US Food and Drug Administration (FDA) has informed that it will extend the Prescription Drug User Fee Act (PDUFA) date to review additional data requested to support the New Drug Application (NDA) for camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) for the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumours have an emergent ESR1 mutation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NDA is based on positive results from the pivotal SERENA-6 Phase III trial presented at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and simultaneously published in The New England Journal of Medicine.1 The FDA granted Breakthrough Therapy Designation for the camizestrant combination in this setting in May 2025.

In April 2026, the FDA’s Oncologic Drugs Advisory Committee did not reach a majority vote in favour of the benefit of switching to camizestrant in combination with a CDK4/6 inhibitor after detection of an ESR1 mutation in circulating tumour DNA (ctDNA) prior to radiographic progression, based on the SERENA-6 Phase III trial. Subsequently, the Company has provided additional analyses requested by the FDA in support of the application, including ctDNA clearance data linked to longer-term efficacy outcomes that will be presented on 02 June at ASCO (Free ASCO Whitepaper) 2026.

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: "We are committed to continuously advancing the clinical landscape in oncology in pursuit of improving outcomes for patients. The SERENA-6 treatment strategy epitomises this approach by monitoring patients for the emergence of ESR1 mutations in ctDNA and testing if a switch of endocrine backbone therapy at this point improves outcomes. We look forward to continuing the dialogue with the FDA in order to bring the benefits of camizestrant with this innovative treatment strategy to eligible patients in the US as quickly as possible."

On 22 May, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of the camizestrant combination in this setting based on the results of the SERENA-6 Phase III trial.

Camizestrant is approved in the United Arab Emirates and Saudi Arabia in this setting. Regulatory applications are also currently under review in Japan and several other countries based on the SERENA-6 Phase III trial.

Notes

HR-positive breast cancer
Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide.2 More than two million patients were diagnosed with breast cancer in 2022, with more than 665,000 deaths globally.2 In the US, breast cancer is the most common cancer in women, with more than 300,000 new cases of the disease diagnosed annually, and more than 42,000 deaths.3 While survival rates are high for those diagnosed with early breast cancer, only about 30% of patients diagnosed with or who progress to metastatic disease are expected to live five years following diagnosis.4

HR-positive breast cancer, characterised by the expression of estrogen or progesterone receptors, or both, is the most common subtype of breast cancer with 70% of tumours considered HR-positive and HER2-negative.4 Estrogen receptor (ERs) often drive the growth of HR-positive breast cancer cells.5

Globally, approximately 200,000 patients with HR-positive breast cancer are treated with a medicine in the 1st-line setting; most frequently with endocrine therapies that target ER-driven disease, which are often paired with CDK4/6 inhibitors.6-8 In the US, approximately 37,000 patients with HR-positive metastatic breast cancer are treated with these therapies in the 1st-line setting.6-8 However, resistance to these therapies develops in many patients.8 Once this occurs, treatment options are limited and survival rates are low with approximately 36% of patients anticipated to live beyond five years after diagnosis.4,8

Mutations in the ESR1 gene are a key driver of endocrine resistance and are associated with poor outcomes, emerging during treatment of the disease and becoming more prevalent as the disease progresses.9,10 Approximately 30% of patients with endocrine sensitive HR-positive disease develop ESR1 mutations during 1st-line treatment before disease progression.6

The optimisation of endocrine therapy and overcoming resistance to enable patients to continue benefiting from these treatments, as well as identifying new therapies for those who are less likely to benefit, are active areas of focus for breast cancer research.

SERENA-6
SERENA-6 is a Phase III, double-blind, randomised trial evaluating the efficacy and safety of camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) versus treatment with an AI (anastrozole or letrozole) in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with HR-positive, HER2-negative advanced breast cancer (patients with either locally advanced disease, or metastatic disease) whose tumours have an emergent ESR1 mutation.

The global trial enrolled 315 adult patients with histologically confirmed HR-positive, HER2-negative advanced breast cancer, undergoing treatment with an AI in combination with a CDK4/6 inhibitor as 1st-line treatment. The primary endpoint of the SERENA-6 trial is PFS as assessed by investigator, with secondary endpoints including OS, and PFS2 by investigator assessment.

Camizestrant
Camizestrant is an investigational, potent, next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist that is currently in Phase III trials for the treatment of HR-positive breast cancer.

AstraZeneca’s broad, robust and innovative clinical development programme, including the SERENA-6, SERENA-4, CAMBRIA-1 and CAMBRIA-2 trials, is evaluating the safety and efficacy of camizestrant when used as a monotherapy or in combination with CDK4/6 inhibitors to address a number of areas of unmet need in HR-positive, HER2-negative breast cancer.

Camizestrant has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations. In the SERENA-2 Phase II trial, camizestrant demonstrated a statistically significant and clinically meaningful improvement in PFS versus Faslodex (fulvestrant) in the overall trial population, including in patients with ESR1 tumour mutations irrespective of prior treatment with CDK4/6 inhibitors in patients with ER-positive locally advanced or metastatic breast cancer, previously treated with endocrine therapy. The SERENA-1 Phase I trial demonstrated that camizestrant is well tolerated and has a promising anti-tumour profile when administered alone or in combination with palbociclib, ribociclib and abemaciclib; three widely used CDK4/6 inhibitors.

(Press release, AstraZeneca, MAY 27, 2026, View Source [SID1234666110])

On May 27, 2026 Ankyra Therapeutics, a clinical-stage biotechnology company pioneering anchored immunotherapy to deliver better outcomes for people with cancer and other serious diseases, reported two poster presentations will be featured at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 to June 2 in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations highlight ongoing Phase 1 clinical trials of tolododekin alfa, a novel IL-12 anchored immunotherapy, including a trial-in-progress poster describing its evaluation in combination with an anti-PD-1/PD-L1 antibody in people with advanced non-small cell lung cancer (NSCLC), as well as baseline quality-of-life data from a separate Phase 1 trial of tolododekin alfa in people with advanced or metastatic solid tumors. These presentations underscore Ankyra’s commitment to advancing anchored immunotherapy as a practical platform design that retains high-dose therapeutics, like IL-12, at the tumor site to deliver enhanced efficacy with lower systemic toxicity.

Presentation details:

Title: A Phase 1b, Two-Arm Study of Tolododekin Alfa (ANK-101) in Combination with an Anti-PD-1/PD-L1 Antibody in Participants with Advanced Non-Small Cell Lung Cancer (NSCLC)

Type: Poster Session
Session: Developmental Therapeutics – Immunotherapy
Abstract: #TPS2678
Poster: #461b
Date / time: Saturday, May 30, 2026; 1:30 – 4:30 pm CDT; Hall A
Lead author: Thomas Marron, MD, PhD, Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine, Mount Sinai, New York
Title: Quality-of-Life in Cancer Patients Treated with Anchored Interleukin-12 (IL-12) Immunotherapy: Results from a First-in-Human Phase 1 Trial of Tolododekin Alfa (ANK-101)

Type: Poster Session
Session: Developmental Therapeutics – Immunotherapy
Abstract: #2593
Poster: #383
Date / time: Saturday, May 30, 2026; 1:30 – 4:30 pm CDT; Hall A
Lead author: Jong Chul Park, MD, Mass General Brigham, Harvard Medical School, Boston
About tolodoken alfa

Tolododekin alfa is an investigational, first-in-class interleukin-12 (IL-12)-anchored immunotherapy. IL-12 is a highly potent proinflammatory cytokine, but its therapeutic use has been limited by toxicity. With Ankyra’s anchoring technology, tolododekin alfa has been shown to deliver and retain high doses of IL-12 in the tumor microenvironment. Early results from an ongoing Phase 1 study show durable retention within tumors, encouraging clinical activity, and a favorable safety profile, with no dose-limiting toxicities across multiple difficult-to-treat solid tumor types. Ankyra is also evaluating tolododekin alfa for the treatment of non-small cell lung cancer and cutaneous squamous cell carcinoma.

(Press release, Ankyra Therapeutics, MAY 27, 2026, View Source [SID1234666126])